Savant Capital LLC Has $36.90 Million Stock Position in Johnson & Johnson $JNJ

Savant Capital LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 11.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 241,544 shares of the company’s stock after selling 31,970 shares during the period. Savant Capital LLC’s holdings in Johnson & Johnson were worth $36,896,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Texas Yale Capital Corp. lifted its position in shares of Johnson & Johnson by 2.5% in the 2nd quarter. Texas Yale Capital Corp. now owns 29,387 shares of the company’s stock worth $4,489,000 after acquiring an additional 705 shares during the period. Raelipskie Partnership lifted its position in Johnson & Johnson by 0.7% in the second quarter. Raelipskie Partnership now owns 13,637 shares of the company’s stock worth $2,083,000 after purchasing an additional 100 shares during the period. Achmea Investment Management B.V. boosted its stake in Johnson & Johnson by 32.5% during the second quarter. Achmea Investment Management B.V. now owns 328,820 shares of the company’s stock worth $50,227,000 after buying an additional 80,593 shares in the last quarter. Golden State Wealth Management LLC raised its stake in shares of Johnson & Johnson by 19.5% in the 2nd quarter. Golden State Wealth Management LLC now owns 4,499 shares of the company’s stock valued at $687,000 after buying an additional 733 shares in the last quarter. Finally, HORAN Wealth LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $2,820,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $186.92 on Friday. The company has a 50 day moving average price of $184.06 and a 200 day moving average price of $168.42. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $450.33 billion, a PE ratio of 18.04, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on JNJ shares. UBS Group upped their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Raymond James Financial increased their target price on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Finally, Loop Capital set a $190.00 price objective on Johnson & Johnson in a report on Wednesday, October 22nd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.